Vedder Thinking | News Deborah L. Lu Quoted in Bloomberg BNA’s Life Sciences Law & Industry Report
January 8, 2014
Deborah L. Lu, Ph.D., Shareholder and member of the firm's Intellectual Property practice group, was quoted in the recent Bloomberg BNA Life Sciences Law & Industry Report article "Personalized Medicine, Patents Top Issues for 2014, Life Sciences Attorneys Say."
This edition of the Life Sciences Law & Industry Report addresses projected major issues in the life sciences industry in 2014 according to attorneys contacted by Bloomberg BNA. Patent-related topics including patent eligibility for genetic material and diagnostic methods, personalized medicine, biosimilars and strategic alliances were issues predicted to be of high importance in 2014. The article then goes on to address the indicated areas of importance and includes commentary from various attorneys on each area.
Dr. Lu weighs in on the topic "Myriad Ruling Leads to Paradox" by saying, "In view of the attacks on Section 101 in Mayo and Myriad, there may be more clarity on 35 U.S.C. § 101 (patent eligibility) with the Alice Corp. v. CLS Bank Intl. case [U.S., No. 13-298, cert. granted Deceber 6, 2013] that has been granted certiorari by the Supreme Court." She adds, "Even though it is a software and business method case, it could lead to ‘abstractness’ affecting bioinformatics patents."
To read this Life Sciences Law & Industry Report in its entirety, please download the attachment below.